New York – March 4, 2014 – Cooley LLP announced today that it advised the underwriters on Amedica Corporation's initial public offering. Amedica is a commercial biomaterial company focused on using its silicon nitride technology platform to develop, manufacture and sell a broad range of medical devices. Amedica now trades on the NASDAQ Capital Market under the symbol "AMDA."
JMP Securities LLC acted as the sole book-running manager for the offering. Needham & Company LLC acted as co-manager for the offering.
The Cooley corporate and securities team advising the underwriters included partners Bo Yaghmaie, Charlie Kim and Darren DeStefano, as well as associates Veer Bhavnagri, Kristin VanderPas, Rebecca Jones, Mark Ballantyne and Dani Nazemian. Critical support for the offering was provided by partners Natasha Leskovsek and Drew Gantt and associates Phil Mitchell and David Sclar (health care & life sciences regulatory); partner Scott Talbot and associate Scott Weston (intellectual property); special counsel Michelle Lara (compensation & benefits) and partner Susan Philpot (tax).
In 2013, Cooley's capital markets practice had a record year, advising on 60 public offerings, including 23 IPOs that raised more than $8.4 billion. Year-to-date in 2014, Cooley has advised on 24 completed public offerings, including 13 completed IPOs. Last year, Cooley attorneys also handled more than 120 M&A transactions, with an aggregate deal value of more than $12.4 billion.
About Cooley LLP
Cooley's attorneys solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and bet-the-company litigation, often where innovation meets the law.
Cooley has more than 750 lawyers across 11 offices in the United States and China.